BioAdvance Capital
03/09/2026 | Press release | Archived content
IVIEW Therapeutics to Present Cutting-Edge Ocular Research at ARVO 2026 in Denver, Colorado
IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced its participation in the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. IVIEW will present one oral presentation and four posters highlighting advancments in dry eye, gene therapy, ocular inflammation, and adenoviral conjunctivitis. The conference will be held from May 3-7, 2026, in Denver, Colorado, and will focus on innovative vision research and precision ophthalmology.
The presentations will feature clinical data, preclinical validation, and formulation innovations across the company's diverse pipeline, including treatments for dry eye disease, postoperative inflammation, glaucoma, and acute adenoviral conjunctivitis.
A key highlight of IVIEW's presence at ARVO will be an oral presentation by Dr. Houman Hemmati, who will discuss results from the Phase 1/2a trial of IVW-1001, a novel ophthalmic eyelid wipe for the treatment of dry eye disease.
IVIEW Therapeutics ARVO 2026 Presentations:
Title: Phase 2B Dose Optimization Study of IVW-1001 Ophthalmic Eyelid Wipe for Dry Eye Disease
Session #226 | Posterboard #: 1759-0521
Date/Time: Monday, May 4, 2026, 11:15 AM - 1:00 PM
Title: IND-Enabling CMC and Nonclinical Toxicology to Support Clinical Development of IVIEW-1701 for the Treatment of Postoperative Ocular Inflammation and Pain
Session #322 | Posterboard #: 2765-0431
Date/Time: Tuesday, May 5, 2026, 8:30 AM - 10:15 PM
Title: GVB-2001, a Novel Gene Therapy to Treat Primary Open-Angle Glaucoma: Preclinical Validation to IIT Clinical Development
Session #342 | Posterboard #: 3022-0272
Date/Time: Tuesday, May 5, 2026, 1:15 PM - 3:00 PM
Title: IVW-1001 Ophthalmic Eyelid Wipe to Treat Dry-Eye Patients: A Phase 1/2a Trial (Oral Presentation)
Session #358 | Presentation #: 3378; Room: Mile High 2B
Date/Time: Tuesday, May 5, 2026, 4:45 PM - 5:00 PM
Title: IVIEW-1201D: A Novel In-situ Gel forming Combination of Povidone-Iodine and Difluprednate for the Treatment of Acute Adenoviral Conjunctivitis
Session #514 | Posterboard #: 5439-0715
Date/Time: Thursday, May 7, 2026, 8:00 AM - 9:45 AM
"We are excited to return to ARVO and share the significant progress we have made across our ophthalmology pipeline," said Dr. Bo Liang, CEO of IVIEW Therapeutics. "The breadth of our presentations-from late-stage clinical development in dry eye to novel gene therapy approaches in glaucoma-underscores our commitment to addressing a wide range of unmet medical needs through cutting-edge science. We look forward to engaging with the scientific community in Denver."
IVIEW Therapeutics invites all ARVO attendees to join them at these sessions to learn more about their groundbreaking research and engage in discussions with their scientific team.
About IVIEW Therapeutics Inc.
IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focusing on innovative ophthalmic therapeutics. Driven by the pursuit of cutting-edge science, the company aims to develop differentiated products that fulfill unmet medical needs. IVIEW invests in novel mechanisms of action and advanced drug delivery technology platforms to bring forward assets with potentially superior target product profiles. Its innovative portfolio of small molecules and gene therapy assets covers dry eye, myopia, conjunctivitis, glaucoma, and presbyopia
BioAdvance Capital published this content on March 09, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 20, 2026 at 13:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]